Precigen Inc
NASDAQ:PGEN
NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

  • LAST PRICE
    0.8201
  • TODAY'S CHANGE (%)
    -0.0628 (-7.1129%)
  • Bid / Lots
    0.8307/ 16
  • Ask / Lots
    0.8440/ 50
  • Open / Previous Close
    0.9200 / 0.8829
  • Day Range
    0.7811
    0.9257
  • 52 Week Range
    0.7811
    1.9300
  • Volume
    1,777,639

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Nov 15, 2024

  • Nov 14, 2024

      Show headlines and story abstract

    • 4:32PM ET on Thursday Nov 14, 2024 by MT Newswires
      Companies Mentioned: PGEN
      04:32 PM EST, 11/14/2024 (MT Newswires) -- ...

    • 4:30PM ET on Thursday Nov 14, 2024 by PR Newswire
      Companies Mentioned: PGEN

      Completed pre-BLA meeting with FDA with full alignment on content of BLA, including CMC module, and path for fourth quarter 2024 rolling BLA submission for PRGN-2012†in RRP under accelerated approval pathway -

    • 4:30PM ET on Thursday Nov 14, 2024 by Dow Jones
      Companies Mentioned: PGEN
      ----------------------------------- -------------------------------------------- Liabilities and Shareholders' Equity Current liabilities Accounts payable $ 4,320 $ 1,726 Accrued compensation and benefits 6,612 8,250 Other accrued liabilities 5,676 6,223 Settlement and Indemnification Accrual 3,213 5,075 Deferred revenue 407 509 Current portion of lease liabilities 988 1,202 ----------------------------------- -------------------------------------------- Total current liabilities 21,216 22,985 Deferred revenue, net of current portion 2,032 1,818 Lease liabilities, net of current portion 4,761 5,895 Deferred tax liabilities 89 1,847 ----------------------------------- -------------------------------------------- Total liabilities 28,098 32,545 Shareholders' equity Common stock - - Additional paid-in capital 2,126,342 2,084,916 Accumulated deficit (2,070,979) (1,964,471) Accumulated other comprehensive income (loss) 13 (1,947) ----------------------------------- -------------------------------------------- Total shareholders' equity 55,376 118,498 ----------------------------------- -------------------------------------------- Total $ 83,474 $ 151,043 liabilities and shareholders' equity =================================== ============================================ Precigen, Inc. and Subsidiaries Consolidated Statements of Operations (Unaudited) Three Months Ended Nine Months Ended (Amounts in thousands, except share and per September 30, September 30, September 30, September 30, share data) 2024 2023 2024 2023 ----------------------- ----------------- ----------------- ------------------ ----------------- Revenues Product revenues $ 66 $ 82 $ 235 $ 730 Service revenues 886 1,296 2,478 4,261 Other revenues 1 1 22 6 ----------------- ----------------- ------------------ ----------------- Total revenues 953 1,379 2,735 4,997 ----------------- ----------------- ------------------ ----------------- Operating Expenses Cost of products and services 1,009 1,537 3,098 4,761 Research and development 11,370 11,583 41,312 35,620 Selling, general and administrative 9,836 9,196 30,293 30,150 Impairment of goodwill - - 1,630 - Impairment of other noncurrent assets - - 32,915 - ----------------- ----------------- ------------------ ----------------- Total operating expenses 22,215 22,316 109,248 70,531 ----------------- ----------------- ------------------ ----------------- Operating loss (21,262) (20,937) (106,513) (65,534) Other Expense, Net Interest expense (2) (1) (6) (461) Interest income 283 856 1,210 2,316 Other income (expense), net (2,985) 281 (2,905) 705 ----------------- ----------------- ------------------ ----------------- Total other income (expense), net (2,704) 1,136 (1,701) 2,560 ----------------- ----------------- ------------------ ----------------- Loss before income taxes (23,966) (19,801) (108,214) (62,974) Income tax benefit (expense) (12) 6 1,706 126 ----------------- ----------------- ------------------ ----------------- Net loss $ (23,978) $ (19,795) $ (106,508) $ (62,848) ================= ================= ================== ================= Net Loss per share Net loss per share, basic and diluted $ (0.09) $ (0.08) $ (0.41) $ (0.26) ================= ================= ================== ================= Weighted average shares outstanding, basic and diluted 275,881,170 248,520,724 259,254,775 243,075,262 ================= ================= ================== =================

    • 4:30PM ET on Thursday Nov 14, 2024 by Dow Jones
      Companies Mentioned: PGEN

      Precigen Reports Third Quarter 2024 Financial Results and Business Updates

      PR Newswire

      GERMANTOWN, Md., Nov. 14, 2024

      -- Completed pre-BLA meeting with FDA with full alignment on content of BLA, including CMC module, and path for fourth quarter 2024 rolling BLA submission for PRGN-2012 in RRP under accelerated approval pathway --

Peers Headlines